170858-33-0

Sonepiprazole is a selective antagonist of the dopamine 4 (D₄) receptor (K_is = 10 nM). It is highly selective over D₁, D₂, and D₃ receptors, serotonin 1A and 2 receptors, as well as α₁- and α₂-adrenergic receptors (K_is > 2,000 nM). Its safety profile in rat studies is improved in comparison to classical antipsychotics but it is not effective for positive or negative symptoms of schizophrenia in patients. In a pharmacological model of stress exposure in rhesus monkeys, sonepiprazole reverses stress-induced cognitive deficits.

Sonepiprazole is a dopamine D4 antagonist with Ki=10 nM.

Store at +4°C

[1] K M MERCHANT. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.[J]. Journal of Pharmacology and Experimental Therapeutics, 1996, 279 3: 1392-1403.
[2] RUTH E. TENBRINK. (S)-(?)-4-[4-[2-(Isochroman-1-yl)ethyl]piperazin-1-yl]benzenesulfonamide, a Selective Dopamine D4 Antagonist[J]. Journal of Medicinal Chemistry, 1996, 39 13: 2435-2437. DOI: 10.1021/jm960084f
[3] MARK H CORRIGAN . Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial[J]. Biological Psychiatry, 2004, 55 5: Pages 445-451. DOI: 10.1016/j.biopsych.2003.10.004
[4] AMY F T ARNSTEN PH.D  Beth M M, PH.D  Kalpana M Ph D. The Selective Dopamine D4 Receptor Antagonist, PNU-101387G, Prevents Stress-Induced Cognitive Deficits in Monkeys[J]. Neuropsychopharmacology, 2000, 23 4: 405-410. DOI: 10.1016/s0893-133x(00)00133-0